Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jun
04
Today In Oncology
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
GLP-1 RAs Associated With Lower Breast Cancer Incidence
American Cancer Society Updates Colorectal Cancer Screening Guideline
Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo